Additionally, our findings show that p53/MCA sarcomas in mice treated with CpG and RT exhibit immune profiles similar to SIC classes D and E in patients with UPS and those classes are associated with better survival outcomes and response rates to anti-PD1 therapy in patients with STS. The gene discussed is PDCD1; the disease is sarcoma.